GGGhulam Mujtaba Ghumman

Ghulam Mujtaba Ghumman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ghulam Mujtaba Ghumman has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BATMAN-Assisted Valve-in-Valve TMVR With Planned Hemodynamic Support in Severe Pulmonary Hypertension

    by Moiz Saeed, Rand Sabanci, Ghulam Mujtaba Ghumman, Ayesha Tahir, Abdul Baqi, Anas Noman, Mohammed Taleb

  • Open Access

    A 25 year nationwide analysis of mortality trends from cerebrovascular diseases in patients with lung cancer (1999–2023)

    by Sarim Hassan Shahab, Aown Abbas, Siddique Ahmed, Hadia Ghazala Masood, Faria Ali, Yazdan Sajid, Warda Imran, Ilsa Fatima, Amir Rafiq, Abubakar Nazir, et al.

    Introduction: The two leading causes of death worldwide are lung cancer and cerebrovascular disease (CVD). Due to complications related to the disease and therapy, patients with lung cancer are much more likely to have a stroke, particularly within 2 years after diagnosis. Results are still poor despite medical advancements, underscoring the necessity of comprehensive prevention and care. Methods: ICD-10 codes for lung cancer (C34) and cerebrovascular illness (I60–I69) were used to evaluate mortality data from CDC WONDER (1999–2023). When both illnesses were listed on death certificates, deaths were counted. Sex, race/ethnicity, area, and urban/rural status were used to compute age adjusted mortality rates (AAMRs). Joinpoint regression was used to evaluate trends, and P < 0.05 was considered significant. Results: Overall AAMR for CVD and lung cancer decreased from 2.19 to 1.44 per 100 000 (APC: −2.9; P < 0.0001) between 1999 and 2015, subsequently increased to 1.71 in 2023 (APC: +2.8; P < 0.0001). From 3.08 in 1999 to 1.98 in 2023, men’s rates were continuously higher than women’s (1.59 to 1.49). The AAMR was highest among NH Black people (it peaked at 2.32 in 2023), followed by NH Whites (1.68) and Hispanics (0.69). Rural areas had higher AAMR than Urban areas. Alaska (2.57), Vermont (2.46), and Mississippi (2.46) had the highest state level burdens, while Utah (0.64) and New Mexico (0.86) had the lowest, while the South and Midwest region saw the sharpest recent rises. Conclusion: Lung cancer mortality from CVD increased until 2023 after decreasing until 2015. The U.S. South, rural areas, Black adults, and men had the biggest burden. To lower stroke mortality in patients with lung cancer, targeted interventions are required, with a focus on addressing racial and rural disparities in care, prevention, and access.

  • Snare-assisted bailout of an embolized Evolut FX transcatheter aortic valve replacement prosthesis using a valve-through-valve balloon-expandable implantation.

    by Ghulam Mujtaba Ghumman, Syed Sohail Ali, Mohammed Taleb

    Transcatheter aortic valve replacement (TAVR) is now the standard of care for severe symptomatic aortic stenosis; however, rare procedural complications such as valve embolization can result in life-threatening consequences. We describe a case of intraprocedural embolization of a self-expanding Medtronic Evolut FX valve into the ascending aorta during deployment. The embolized prosthesis was stabilized with a snare and parked distal to the sinotubular junction. Because a second self-expanding valve could not be advanced across the displaced frame, a 23 mm balloon-expandable Edwards SAPIEN 3 Ultra RESILIA valve was successfully delivered through the embolized prosthesis and deployed in the native annulus. This cross-platform valve-through-valve bailout restored durable valve function without surgery and underscores the importance of procedural adaptability in managing complex TAVR complications.

  • Open Access

    Percutaneous Aspiration for IVDU–Associated Infective Endocarditis

    by Ghulam Mujtaba Ghumman, Anas Noman, Tarif Kanaan, Fnu Zafrullah, Syed Sohail Ali, Mohammed Taleb


  • Outcomes of Watchman device implantation in atrial fibrillation patients contraindicated for long-term anticoagulation: a single-center experience

    by Ghulam Mujtaba Ghumman

    Background: Left atrial appendage occlusion (LAAO) using the Watchman device is an established strategy for stroke prevention in atrial fibrillation (AF) patients at high thromboembolic risk who cannot tolerate long-term oral anticoagulation (OAC). Objectives: To evaluate short-term clinical and echocardiographic outcomes of Watchman implantation in AF patients with contraindications to long-term OAC. Methods: We conducted a retrospective single-center study of AF patients who underwent Watchman implantation between September 01, 2023, and March 01, 2025. Baseline demographics, comorbidities, procedural characteristics, complications, antithrombotic strategies, and 45-day outcomes were analyzed. Outcomes were compared between patients with and without follow-up TEE. Data were analyzed using SAS v9.4. All tests were two-tailed, and a p-value 5 mm), and none had device-related thrombus. Clinical outcomes included one hemorrhagic stroke (1.1%) and eight rehospitalizations (7.6%, 95% CI 3.4-14.5%), unrelated to the device. No ischemic strokes were observed. Conclusion: Watchman implantation achieved a 100% success rate with low complication rates and favorable short-term clinical and echocardiographic outcomes in AF patients contraindicated for long-term anticoagulation.

  • Open Access

    Smart bioactive hydrogels for myocardial infarction repair: a multifunctional approach integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing

    by Abubakar Nazir, Awais Nazir, Naseer Khan, Muhammad Shah Wali Jamal, Abdalhakim Shubietah, Imran Naqvi, Syed Rafay Hussain Zaidi, Behram Khan, Ghulam Mujtaba Ghumman, Ahmed Jamal Chaudhary, et al.

    Background: Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, necessitating advanced therapeutic strategies for cardiac repair. Conventional treatments often fail to restore cardiac function effectively, highlighting the need for innovative biomaterials. Smart bioactive hydrogels have emerged as promising candidates due to their ability to provide structural support, controlled drug delivery, electroconductivity, and real-time biosensing capabilities. Objective: This review explores the multifunctional role of smart bioactive hydrogels in MI repair, focusing on their stimuli-responsive drug delivery, electroconductive properties, and biosensing potential. Methods: This narrative review synthesized recent advances in multifunctional smart bioactive hydrogels for MI repair, focusing on systems integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar for studies published between 2010 and 2025 using relevant keywords. Articles were included if they addressed hydrogel-based platforms featuring at least one of the following: responsive drug release (e.g., pH, temperature, and enzymatic), conductive components (e.g., carbon nanotubes and graphene), or embedded biosensing technologies. Studies limited to conventional hydrogels without multifunctionality were excluded. Relevant data were extracted and thematically categorized by material composition, functional properties, regenerative potential, and translational applicability, with emphasis on preclinical cardiac models. No quantitative synthesis was performed due to heterogeneity across study designs. Results: Smart bioactive hydrogels have demonstrated significant potential for MI repair by integrating stimuli-responsive drug delivery, electroconductivity, and biosensing within a single therapeutic platform. pH-, ROS-, and enzyme-sensitive systems enable localized, on-demand release of angiogenic factors or cardioprotective drugs, leading to 20–45% infarct size reduction and 1.5–2.3-fold increases in neovascular density in preclinical models. Incorporation of conductive materials such as graphene oxide (GO), polypyrrole, or carbon nanotubes (CNT) has been shown to restore electrical coupling, improve connexin-43 expression, and enhance left ventricular ejection fraction by 8–15%, while narrowing QRS complex duration by ~15 ms in large-animal studies. Emerging biosensing-enabled hydrogels permit real-time monitoring of local biochemical cues, such as pH, oxygen levels, and inflammatory cytokines, maintaining stable signal fidelity for up to 4 weeks without adverse tissue reactions. Advances in 3D/4D bioprinting now allow spatially patterned integration of these functionalities, enabling region-specific therapeutic release and conductivity optimization. Collectively, these multifunctional hydrogels exhibit superior regenerative outcomes compared to conventional scaffolds and hold strong translational promise, although variability in experimental design, lack of standardized endpoints, and limited long-term clinical data remain challenges to widespread adoption. Conclusion: Smart bioactive hydrogels represent a transformative approach in MI repair by combining structural support with multifunctional properties. Their ability to deliver therapeutics on demand, enhance electroconductivity, and enable real-time biosensing offers new possibilities for precision cardiac medicine.


  • Transcatheter Aortic Valve Replacement in Patients With Severe Rheumatic Aortic Stenosis: A Proportional Meta‐Analysis

    by Muhammad Junaid Ahsan, Soban Ahmad, Ghulam Mujtaba Ghumman, Mariam Dvalishvili, Shahbaz A. Malik, Ashequl M. Islam, Andrew M. Goldsweig

  • Open Access

    Dilemma of ST-Segment Elevation and Subarachnoid Hemorrhage: A Case Report and Literature Review

    by Ghulam Mujtaba Ghumman, Nagabindhu Aravapalli, Fnu Salman, Mohammed Taleb, Sohail S. Ali

    Acute ST-segment elevation myocardial infarction (STEMI) occurs due to occlusion of one or more coronary arteries causing myocardial injury. It is a medical emergency and requires prompt diagnosis and intervention. Transient ST-segment elevation can occur due to coronary vasospasm, and their association has been reported with subarachnoid hemorrhage. We present a distinct case of ST-segment elevations in inferior leads with reciprocal ST-depressions in lateral leads, indicating STEMI that leads to complete heart block and ventricular fibrillation cardiac arrest in a patient with subarachnoid hemorrhage. The coronary angiogram was negative for any obstructive coronary artery disease.

  • Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

    by Muhammad Shayan Khan, Ghulam Mujtaba Ghumman, Abdul Baqi, Jay Shah, Muhammad Aziz, Tanveer Mir, Ayesha Tahir, Srinivas Katragadda, Hemindermeet Singh, Mohammed Taleb, et al.

    Background Pemafibrate is a novel fibrate class drug that is a highly potent and selective agonist of peroxisome proliferator-activated receptor α (PPARα). We performed the first ever network meta-analysis containing the largest ever group of patients to test the efficacy of pemafibrate in improving lipid levels compared with fenofibrate and placebo in patients with dyslipidemia. Methods Potentially relevant clinical trials were identified in Medline, PubMed, Embase, clinicaltrials.gov, and Cochrane Controlled Trials registry. Nine randomized controlled trials met the inclusion criteria out of 40 potentially available articles. The primary effect outcome was a change in the levels of triglycerides (TG), high-density lipoproteins (HDL), or low-density lipoproteins (LDL) before and after the treatment. Results A total of 12,359 subjects were included. The mean patient age was 54.73 (years), the mean ratio for female patients was 18.75%, and the mean examination period was 14.22 weeks. The dose for pemafibrate included in our study was 0.1, 0.2, or 0.4 mg twice daily, whereas the dose for fenofibrate was 100 mg/day. Data showed a significant reduction in TG and a mild increase in HDL levels across the pemafibrate group at different doses and fenofibrate 100 mg group (with greatest effect observed with pemafibrate 0.1 mg twice daily). A mild increase in LDL was also observed in all groups, but the increase in LDL in the 0.1 mg twice daily dose group was statistically insignificant. Conclusion Pemafibrate 0.1 mg twice daily dose led to highest reduction in TG levels and the highest increase in HDL levels compared with other doses of pemafibrate, fenofibrate, and placebo.


  • Open Access

    C-58 | The In-Hospital Outcomes of Atherectomy for Peripheral Arterial Disease Among Obese and Non-Obese Patients: An Insight from the National Inpatient Sample Database

    by Kritika Luthra, Ghulam Mujtaba Ghumman, Jay Shah, Muhammad Shayan Khan, Abdul Baqi, Amir Khan, Fnu Salman, Moaaz Baghal, Nadia Aslam, Hemindermeet Singh, et al.